The Recombinant Antibodies & Mimetics Database: Redefining the future of antibody use in science

Antibodies are indispensable tools in biomedical research, yet the widespread use of animal-derived antibodies contributes to poor reproducibility and raises serious ethical concerns. Many commercial antibodies fail to bind their intended targets, leading to irreproducible results, wasted resources and stalled progress. In Europe alone, over a million animals are used annually for antibody production. Non-animal-derived recombinant antibodies and antibody mimetics offer a scalable, scientifically valid alternative. Endorsed by the European Union Reference Laboratory for alternatives to animal testing (EURL ECVAM), these reagents deliver greater consistency, transparency and ethical alignment. Despite their advantages, they are currently estimated to make up less than 5% of research reagents, held back by limited awareness, access barriers and persistent misconceptions about performance. To address these challenges, the Centre for Human Specific Research developed the open-access Recombinant Antibodies & Mimetics Database. This platform links researchers to ethically sourced, sequence-defined affinity reagents and features a unique colour-coded classification system to clearly indicate the extent of animal involvement. By improving transparency, the database empowers informed decision-making and supports alignment with best practices. More than a sourcing tool, the platform drives advocacy for systemic change, encouraging funders, institutions, publishers and regulators to prioritise recombinant antibodies and antibody mimetics. Its ultimate aim is to make high-quality animal-free recombinant and mimetic antibodies the global standard, supporting a more reproducible, ethical and forward-looking future for antibody science.